Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma

Trial Profile

Randomized Non Comparative Phase II Trial With Bevacizumab and Fotemustine in the Treatment of Recurrent Glioblastoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2016

At a glance

  • Drugs Bevacizumab (Primary) ; Fotemustine
  • Indications Glioblastoma
  • Focus Therapeutic Use
  • Sponsors Roche
  • Most Recent Events

    • 02 Jun 2015 Results presented at the 51st Annual Meeting of the American Society of Clinical Oncology.
    • 27 Jan 2014 As per the ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
    • 23 May 2013 Planned end date changed from 1 Dec 2014 to 1 Nov 2014 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top